Abstract: Aspects of the present disclosure relate to a control system, system and method for controlling a transition between a first driving mode and a second driving mode of a vehicle. The present disclosure relates to receiving image data of an occupant of the vehicle; quantifying one or more characteristics of the occupant's gaze based at least in part on the received image data, the one or more characteristics being indicative of the occupant's attention to a non-driving task; determining a transition profile for transitioning between the first driving mode and the second driving mode based at least in part on the one or more characteristics of the occupant's gaze; and generating and outputting a control signal to transition from the first driving mode to the second driving mode, the control signal comprising instructions for controlling one or more vehicle systems in accordance with the determined transition profile.

Abstract: The invention provides light-emitting compositions, including lasing and fluorescent compositions. The invention particularly relates to programmable biological substrates, which fluoresce and/or lase, and which have a wide variety of different applications. The invention extends to use of the fluorescent compositions and lasing compositions comprising programmable biological substrates in fabricating lasers, and in various biological imaging applications, such as in assays.

Abstract: The invention relates to a control device (1) for a vehicle for determining the perceptual load of a visual and dynamic driving scene. The control device is configured to: ?receive a sensor output (101) of a sensor (3), the sensor (3) sensing the visual driving scene, ?extract a set of scene features (102) from the sensor output (101), the set of scene features (102) representing static and/or dynamic information of the visual driving scene, ?determine the perceptual load (104) of the set of extracted scene features (102) based on a predetermined load model (103), the load model (103) being predetermined based on reference video scenes each being labelled with a load value, ?map the perceptual load to the sensed driving and ?determine a spatial and temporal intensity distribution of the perceptual load across the sensed driving scene. The invention further relates to a vehicle, a system and a method.

Abstract: A non-viral delivery complex comprising a cationic core which is a nanoparticle comprising a peptide having a polycationic nucleic acid binding component, a cleavable spacer element and a cell surface receptor binding component; a nucleic acid and optionally a cationic lipid; and an anionic liposomal coating surrounding the cationic core, said coating comprising lipids from a subject's cells. Also related formulations, uses and methods.

Abstract: A nerve interface device including at least one cuff portion having an assembled position in which the cuff portion forms at least part of a passageway for receiving a nerve along a longitudinal axis passing through the passageway; and first and second rings of electrodes mounted on the at least one cuff portion, each ring of electrodes including a plurality of electrodes. Each electrode in the first ring has a corresponding longitudinally-aligned electrode in the second ring so as to form a plurality of pairs of electrodes spaced apart from each other along the longitudinal axis. The plurality of pairs of electrodes includes at least a first pair of electrodes, the first pair of electrodes mounted on the at least one cuff portion. The at least one cuff portion includes an asymmetric configuration about a central axis perpendicular to the longitudinal cuff axis.

Abstract: There is provided a nerve activity monitoring method that includes receiving an input signal indicative of activity in a nerve of a subject; receiving physiological data indicative of physiological activity in the subject; establishing a relationship between the physiological data and the input signal; identifying a plurality of periodic portions in the input signal based on the relationship between the physiological data and the input signal; and outputting the periodic portions identified.

Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ?-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

Abstract: A process for producing a solid pharmaceutical dosage formulation, said process comprising powder bed fusion selective laser 3-dimensional printing of a mixture comprising: (a)a drug; and (b)an excipient; whereinat least one of said drug and said excipient absorbs electromagnetic radiation at a wavelength emitted by the laser; or (a)a drug; (b)an excipient; and (c)an absorbent material which absorbs electromagnetic radiation at a wavelength emitted by the laser.

Abstract: The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.

Abstract: A device for monitoring adherence of a patient to a prescribed regimen is provided. The device has a pulmonary delivery device fluid, an adapter in communication with the delivery device and a dispenser in fluid communication with the adapter. A pressurized drug, contained in the pulmonary delivery device, can be delivered from the pulmonary delivery device to the patient through the adapter and the dispenser. A sensor is mounted to the adapter or the dispenser for detecting a temperature or pressure change caused by the movement of the drug from the pulmonary delivery device to the patient and generating a feedback signal based on the change. The feedback signal is further processed for generating a signal indicating a successful deliver of the drug to the patient.

Abstract: Bioprosthetic heart valves and methods for fabricating bioprosthetic heart valves are provided. Biological tissue is attached to biocompatible material. The biocompatible material is folded to form a tubular structure with the attached biological tissue located on the inner surface of the tubular structure, the biological tissue forming leaflets of the heart valve. A stent is secured around the outer surface of the tubular structure. A region of the biocompatible material is cut. The biocompatible material is folded at the cut region away from the tissue and around the downstream edge of the stent and is secured to the stent's outer surface. The biocompatible material is folded at the upstream end of the tubular structure around the upstream edge of the stent and attached to the stent's outer surface so that the stent's inner and outer surfaces are covered with no more than a single layer of the biocompatible material.

Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional ?-galactosidase A protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described is a vector, host cell or transgenic animal comprising the nucleic acid molecule; and a pharmaceutical composition comprising the nucleic acid molecule or the vector. Further, the use of the nucleic acid molecule in a method of treating Fabry disease is described.

Abstract: Disclosed is a method for assistance with the establishment of a diagnosis of a patient, starting from at least one identified sign, and based on a computerized knowledge database including a medical ontology. The medical ontology includes: a list of signs forming a “sign” class; a list of pathological states forming a “pathological state” class; and a first set of logical relationships between the signs and the pathological states, each logical relationship establishing a correlative link between a sign and a pathological state. The method includes: a step of searching for potential pathological states, linked to at least one of the identified signs by the first set of logical relationships; and a step of identifying potential signs in which, for each potential pathological state, all of the signs linked by a correlative link to the potential pathological state are identified by the first set of logical relationships.

Abstract: The present invention lies in the field of 3D surveying, mapping, and imaging. In particular, the present invention relates to the rotational alignment of 3D datasets. Embodiments include an apparatus method and program for rotational and optionally also translational alignment of 3D datasets. The 3D datasets being stored as point clouds, transformed into vector sets, and the vector sets being represented as a unit sphere or Gaussian sphere and compared for best alignment. The found best alignment is used to rotate the two 3D datasets into rotational and translational alignment with one another.

Abstract: The present invention relates generally to methods and materials for use in photothermal or sonodynamic therapy. The invention novel nanoparticles for use in delivering sensitizers to solid tumour target, wherein the nanoparticles are composed of a polymers or co-polymer of monomers linked by peptide bonds, wherein the polymer or co-polymer comprises one or both of glutamate or derivatised glutatamic acid, and optionally a further, different, monomer which is a naturally occurring amino acid or synthetic monomer having a side chain group, wherein the polymer or co-polymer is not composed only of glutamate. The pendant groups and/or side chains of the polymer or co-polymer interact non-covalently with the sensitizer.

Abstract: The invention relates to a control device (1) for a vehicle for determining the perceptual load of a visual and dynamic driving scene. The control device is configured to: receive a sensor output (101) of a sensor (3), the sensor (3) sensing the visual driving scene, extract a set of scene features (102) from the sensor output (101), the set of scene features (102) representing static and/or dynamic information of the visual driving scene, and determine the perceptual load (104) of the set of extracted scene features (102) based on a predetermined load model (103), wherein the load model (103) is predetermined based on reference video scenes each being labelled with a load value The invention further relates to a system and a method.

Abstract: A band (1) comprising, on its inner surface, an irregular array of tacky areas or protrusions (6) that dissipate foci of stress in the skin (of the abdominal wall or other body areas). Wearing such a band around the abdomen is intended to help prevent the occurrence of stretch marks.

Abstract: The invention provides expression vectors, nucleic acids, vector particles and methods of treatment involving these vector particles, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, as well as methods of confirming the presence of engineered KCNA1 mRNA in a cell. The features of the engineered KCNA1 gene combine to advantageously enhance the translation and activity of the Kv1.1 protein and improve detection of KCNA1 gene expression in a cell and can be used for example in the treatment of epilepsy and similar neurological disorders.

Abstract: The present invention relates generally to methods and materials for use in photothermal or sonodynamic therapy. The invention novel nanoparticles for use in delivering sensitizers to solid tumour target, wherein the nanoparticles are composed of a polymers or co-polymer of monomers linked by peptide bonds, wherein the polymer or co-polymer comprises one or both of glutamate or derivatised glutatamic acid, and optionally a further, different, monomer which is a naturally occurring amino acid or synthetic monomer having a side chain group, wherein the polymer or co-polymer is not composed only of glutamate. The pendant groups and/or side chains of the polymer or co-polymer interact non-covalently with the sensitizer.

Abstract: There is described a gene therapy approach for treating Wilson's disease in which a nucleic acid molecule is used which comprises a nucleotide sequence encoding for a functional ATP7B protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described are vectors comprising the nucleotide sequence and methods and uses thereof.